A rapid urine test for invasive aspergillosis cleared its way through the FDA after clinical validation work from Johns Hopkins Medicine. The clearance centers on using urine as a faster sampling matrix to aid diagnosis of invasive aspergillosis, a condition with high morbidity in immunocompromised patients. For labs and hospitals, the key change is operational: urine-based workflows can simplify sampling and logistics compared with more invasive specimen collection, potentially improving turnaround time for clinicians managing suspected invasive fungal disease. The validation package described in the study supports the clinical performance needed for the FDA clearance, strengthening diagnostic options for a disease where early identification can determine eligibility for antifungal therapy and downstream outcomes.